News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
The annual B.PHL Innovation Festival serves as a gathering place for creatives, entrepreneurs, leaders, students, and industry change makers.
Tumors within the heart affect thousands of patients around the world annually, but prior to the ŌNŌ system, open-heart surgery was the only way to remove them.
Dr. Yamada had a distinguished career as a visionary leader in the life sciences industry. He led research and development at Takeda Pharmaceutical Co. and GlaxoSmithKline.
Exelon Corporation and the non-profit Exelon Foundation are searching for promising early-stage companies to invest in for the 4th annual Climate Change Investment Initiative (2c2i).
Lumify Care and Neuralert have grown rapidly in terms of funding and product expansion.
Shinkei Systems cuts down on waste by reducing the likelihood that off-target species would be caught and killed, and streamlining the process to avoid waste.
The research identifies the protein IFT80 as a key player in regulating populations of osteoclasts, cells that break down bone.
Researchers are preparing to launch the first human trial to see how the gum affects active COVID-19 patients.
"We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me."
Rosa's experience working in the lab and participating in the PCI Fellows program at Penn helped her gain valuable experience for her career at Deloitte.